Eravacycline in Critically Ill Patients with Multidrug-Resistant Gram-Negative Infections: A Real-World Cohort Study

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Pharmacology

Background:

• Multidrug-resistant Gram-negative infections pose a significant threat in intensive care units (ICUs).
• Carbapenem-resistant pathogens present limited treatment options for critically ill patients.
• Real-world data on eravacycline use in high-acuity ICU populations is limited.

Purpose of the Study:

• To evaluate the effectiveness and safety of eravacycline as salvage therapy for multidrug-resistant Gram-negative infections in critically ill ICU patients.
• To identify factors associated with outcomes in patients receiving eravacycline for severe infections.

Main Methods:

• Retrospective cohort study of adult ICU patients receiving eravacycline for multidrug-resistant Gram-negative infections.
• Data collected included demographics, clinical status, microbiology, and treatment details.
• Outcomes assessed were in-hospital mortality, clinical response, microbiological eradication, and safety.

Main Results:

• Forty critically ill patients were included, with high rates of pulmonary and intra-abdominal infections.
• Klebsiella pneumoniae was the predominant pathogen, followed by Acinetobacter baumannii and Pseudomonas aeruginosa.
• Despite 60% microbiological eradication, in-hospital mortality was high at 75%, linked more to disease severity than treatment timing.

Conclusions:

• Eravacycline salvage therapy demonstrated moderate microbiological response but high mortality in this ICU cohort, reflecting severe underlying illness.
• Host factors and systemic inflammation appear more critical to survival than pathogen clearance alone.
• Further controlled studies are needed to establish eravacycline's efficacy beyond complicated intra-abdominal infections.